Vertex Pharmaceuticals insiders complete planned share sales
Between November 12 and November 16, 2026, three executives and directors at Vertex Pharmaceuticals Inc. sold company shares under pre-arranged plans.
Key points
- Charles F. Wagner Jr., executive vice president and chief financial officer, sold 15,286 shares at an average price of 547.87 USD on November 12, 2026.
- On November 13, 2026, Capital Research Global Investors reported owning 17,821,661 shares of Vertex Pharmaceuticals Inc., representing 7.0% of the total class shares.
Insider transactions
Charles F. Wagner Jr., executive vice president and chief financial officer, sold 15,286 shares at an average price of 547.87 USD on November 12, 2026.
On November 16, 2026, director Sangeeta N. Bhatia sold 271 shares, and director Nancy Thornberry sold 1,000 shares. Both transactions were executed at a price of 547.86 USD per share under 10b5-1 plans, which are preset selling schedules executives set up in advance to help minimize insider trading risks.
Value of shares sold, by insider
Following Vertex Pharmaceuticals Inc / MA? Get notified when the next 10-Q, Form 4 or guidance change drops.
Changes in shareholder structure
On November 13, 2026, Capital Research Global Investors reported owning 17,821,661 shares of Vertex Pharmaceuticals Inc., representing 7.0% of the total class shares.
What to check next
Shareholders should monitor future insider transaction reports on the SEC platform to track any further changes in share ownership.
Explore Vertex Pharmaceuticals Inc / MA on Insider
Original sources
- SCHEDULE 13G/A filing, November 13, 2026
- 4 filing, November 16, 2026
- 4 filing, November 18, 2026
- 4 filing, November 18, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Vertex Pharmaceuticals Inc / MA
A notification in your browser or on your phone when we publish about Vertex Pharmaceuticals Inc / MA. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
